Stockscreener 앱 받기
0.00
100.00%
-3.41
전일 마감가:
$3.41
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$11.14M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
+0.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$3.46
52주 변동 폭
$0.00
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
CSCI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSCI
Cosciens Biopharma Inc
|
0.00 | 11.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cosciens Biopharma Inc 주식(CSCI)의 최신 뉴스
TSX:CSCI Forum Post | prophetoffactz-36604398 | PGX-YBG | COSCIENS Biopharma Inc - Stockhouse
COSCIENS Biopharma reports on forward-looking statements By Investing.com - Investing.com South Africa
COSCIENS Biopharma Announces Virtual Shareholder Meeting on June 30, 2025 - TipRanks
COSCIENS Biopharma reports on forward-looking statements - Investing.com
AEZSAeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders - mx.advfn.com
COSCIENS Biopharma reconstitutes board - MSN
COSCIENS BiopharmaEnters Resolution Agreement With Goodwood, Goodwood Fund, And Puccetti Funds Management - marketscreener.com
COSCIENS Biopharma Schedules Virtual Annual Meeting for June 30, 2025 - TipRanks
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Share - GuruFocus
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | CSCI Stock News - GuruFocus
Cosciens Biopharma Brief: Entering Into a Resolution Agreement With Goodwood Inc. As Co Reconstitutes Board for Benefit of Shareholders - marketscreener.com
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders - The Manila Times
COSCIENS Biopharma Overhauls Board with Pharma Veterans After 8.2% Stakeholder Agreement - Stock Titan
Cosciens Biopharma announces receipt of Goodwood intended director nominations - Yahoo Finance
COSCIENS Biopharma Receives Director Nominations Ahead of Shareholder Meeting - TipRanks
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Directo - GuruFocus
COSCIENS Biopharma Receives Director Nominations from Goodwood - TipRanks
COSCIENS Biopharma Inc. Acknowledges Director Nominations from Goodwood Fund Ahead of Annual Shareholder Meeting - Nasdaq
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - The Manila Times
Cosciens Biopharma Brief: Acknowledging Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - marketscreener.com
Activist Investor Goodwood Nominates 6 Directors to COSCIENS Board | CSCI Stock News - Stock Titan
Goodwood Seeks Board Overhaul At Cosciens Biopharma - Finimize
Goodwood to Nominate New Directors for COSCIENS Biopharma Inc. - The Globe and Mail
Goodwood To Nominate New Directors For COSCIENS Biopharma Inc. - Barchart.com
Databricks Announces 2025 Data + AI Summit Keynote Lineup and Data Intelligence Programming - The Globe and Mail
COSCIENS Biopharma Reports Q1 2025 Results and Updates - TipRanks
COSCIENS Biopharma reports key corporate updates By Investing.com - Investing.com India
COSCIENS Biopharma reports key corporate updates - Investing.com
COSCIENS Biopharma Completes Merger with Ceapro and Restructures Governance - TipRanks
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE) - The Globe and Mail
COSCIENS Biopharma: Q1 Earnings Snapshot - CT Insider
COSCIENS Biopharma reports Q1 2025 results, updates strategy By Investing.com - Investing.com Nigeria
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Res - GuruFocus
COSCIENS Biopharma reports Q1 2025 results, updates strategy - Investing.com
COSCIENS Biopharma Reports Q1 2025 Results and Strategic Updates - TipRanks
COSCIENS Biopharma Reports Q1 2025 Financial Results Amid Strategic Shifts - TipRanks
Cosciens Biopharma Brief: Appointing Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer - marketscreener.com
Cosciens Biopharma Brief: Company Says Ended Quarter with US$13.8 Million in Cash - marketscreener.com
Cosciens Biopharma Brief: Reported a Q1 Consolidated Net Loss of US$3.7 Million, or $1.16 Loss Per Common Share - marketscreener.com
COSCIENS Biopharma Inc. Transitions to Pure-Play Natural Products Company, Announces Phase 2 Clinical Trial Advancements and New CEO Appointment - Nasdaq
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Yahoo Finance
COSCIENS Earnings Reveal Strategic Pivot to Natural Products While Advancing Key Clinical Trial - Stock Titan
COSCIENS Biopharma Inc. Reports Transformative Year - TipRanks
COSCIENS Biopharma Sets Date for Annual Meeting Amid Strategic Shifts - TipRanks
Fennec Pharmaceuticals: Top 10 Undervalued Biotechnology Industry Stocks (FRX) - The Globe and Mail
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
COSCIENS Biopharma appoints Anna Biehn as new CEO amid leadership change - N24.com.tr
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Bi - GuruFocus
COSCIENS Biopharma (CSCI) Names Anna Biehn as New CEO | CSCI Sto - GuruFocus
COSCIENS Biopharma names new CEO Anna Biehn By Investing.com - Investing.com Canada
COSCIENS Biopharma names new CEO Anna Biehn - Investing.com Australia
Cosciens Biopharma Inc (CSCI) 재무 분석
Cosciens Biopharma Inc (CSCI)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.68%
0.50%
자본화:
|
볼륨(24시간):